WallStSmart

Apyx Medical Inc (APYX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 64168% more annual revenue ($37.54B vs $58.41M). MDT leads profitability with a 13.9% profit margin vs -14.8%. APYX appears more attractively valued with a PEG of 0.59. MDT earns a higher WallStSmart Score of 68/100 (B-).

APYX

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 7.7Quality: 4.5
Piotroski: 3/9Altman Z: -0.32

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APYXUndervalued (+31.2%)

Margin of Safety

+31.2%

Fair Value

$5.70

Current Price

$2.90

$2.80 discount

UndervaluedFair: $5.70Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APYX2 strengths · Avg: 8.0/10
PEG RatioValuation
0.598/10

Growing faster than its price suggests

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

APYX4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$129.74M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : APYX

The strongest argument for APYX centers on PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : APYX

The primary concerns for APYX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.72 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

APYX profiles as a growth stock while MDT is a value play — different risk/reward profiles.

APYX carries more volatility with a beta of 1.35 — expect wider price swings.

APYX is growing revenue faster at 22.1% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 38/100) and 13.7% revenue growth. APYX offers better value entry with a 31.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apyx Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?